Skip to main content
← All trials
Plaque PsoriasisDrugPhase 2

What this study is

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

What's being tested

  • ORKA-001

    Intervention · DRUG

    ORKA-001 administered by subcutaneous (SC) injection

Study details

Official title
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis
Sponsor
Oruka Therapeutics, Inc.
Conditions
Plaque Psoriasis
Enrolling
240 people
Starts
2026-02-23
Est. completion
2030-07
Design
Open-label, non-randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗